Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals' stock price has experienced significant volatility and a notable decline. Key events impacting the stock include a reverse stock split in December 2025, efforts to regain Nasdaq compliance, equity offerings in the summer of 2025 and January 2026, positive clinical updates from its Phase 2 study for NGC-Cap, and insider buying activity.

There is no specific information available regarding demand seasonality for Processa Pharmaceuticals, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its products are currently in development and not yet commercially available, which typically means demand seasonality is not a relevant factor at this stage.

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Next Generation Chemotherapy oncology drug products and advancing select non-oncology programs. The company's strategy involves modifying existing FDA-approved cancer drugs to improve safety and efficacy. Its pipeline includes NGC-Cap (PCS6422 + Capecitabine) in Phase 2 for breast cancer and being developed for metastatic colorectal cancer, PCS11T (NGC-Irinotecan) as a preclinical oncology asset, PCS499 which completed a Phase 2b clinical trial for necrobiosis lipoidica and is being explored for primary glomerular diseases, and PCS12852 which completed a Phase 2 clinical trial for gastroparesis and constipation disorders.

Processa Pharmaceuticals is headquartered in Vero Beach, Florida, with its corporate office in Hanover, MD. The company focuses on developing drug products for patients with unmet medical needs in the United States.

Processa Pharmaceuticals actively works to build its brand reputation through engagement with the scientific and investment communities by participating in major industry and scientific conferences. A licensing deal with Intact Therapeutics in June 2025 and positive clinical updates from the Phase 2 study of NGC-Cap have positively affected its reputation.

Processa Pharmaceuticals has a mix of institutional and individual owners. Major institutional owners include Jane Street Group, Llc, Vanguard Group Inc, and Hrt Financial Lp. James E. Besser is the largest individual shareholder. HX Entertainment Limited also holds a notable percentage of shares.